Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? A narrative review
Journal
Cancers
Journal Volume
12
Journal Issue
9
Pages
1-18
Date Issued
2020
Author(s)
Abstract
Pemetrexed is currently mainly considered for the treatment of advanced nonsquamous non-small-cell lung cancer (NSCLC) negative for gene mutations/rearrangements (wild-type disease (WTD)). This narrative review aimed to highlight the role of pemetrexed in the treatment of onco-driven nonsquamous advanced NSCLC by reviewing published clinical studies. For epidermal growth factor receptor (EGFR) mutations, patient survival following first-line pemetrexed–platinum was longer than for WTD. Later-line pemetrexed-based treatment after tyrosine kinase inhibitor (TKI) failure provided greater benefits than non-pemetrexed regimens. First-and later-line pemetrexed-based therapy also provided survival benefits in patients with anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 (ROS1) rearrangements. In patients with rearranged during transfection (RET) proto-oncogene rearrangements, survival with pemetrexed was similar to that in ALK-and ROS1-positive patients and longer than that in patients with Kirsten rat sarcoma (KRAS) virus proto-oncogene mutations or WTD, although the available studies were limited. For Erb-b2 receptor tyrosine kinase 2 (ERRB2) mutations, first-line pemetrexed showed outcomes similar to those for EGFR and KRAS alterations. Data on pemetrexed in patients with KRAS mutations or MNNG HOS-transforming (MET) expression were limited. Pemetrexed could be an option for first-and second-line treatment for TKI failure in nonsquamous advanced NSCLC with select targetable driver mutations. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Subjects
Chemotherapy; Gain of function mutation; Non-small-cell lung cancer; Pemetrexed; Progression-free survival
SDGs
Other Subjects
afatinib; alectinib; anaplastic lymphoma kinase; atezolizumab; brigatinib; cabozantinib; capmatinib; carboplatin; ceritinib; cisplatin; crizotinib; dabrafenib; dacomitinib; durvalumab; entrectinib; epidermal growth factor receptor; erlotinib; gefitinib; K ras protein; larotrectinib; lorlatinib; nivolumab; osimertinib; pembrolizumab; pemetrexed; selpercatinib; selumetinib; trametinib; trastuzumab; advanced cancer; cancer combination chemotherapy; EGFR gene; ERRB2 gene; gene expression; gene mutation; gene rearrangement; HER2 gene; human; monotherapy; non small cell lung cancer; oncogene K ras; progression free survival; proto oncogene; RET gene; Review; ROS1 gene
Publisher
MDPI AG
Type
review